Crinetics Gross Profit from 2010 to 2024

CRNX Stock

USD 56.77 0.68 1.21%

Crinetics Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Crinetics Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2016-12-31

Previous Quarter

166 K

Current Value

-354 K

Quarterly Volatility

5.5 M

Covid

Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Interest Income of 14.1 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 4.02. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Latest Crinetics Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Crinetics Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Crinetics Pharmaceuticals minus its cost of goods sold. It is profit before Crinetics Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Crinetics Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (125.49 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Crinetics Gross Profit Regression Statistics

	Arithmetic Mean	(1,402,090)
	Geometric Mean	2,790,793
	Coefficient Of Variation	(288.71)
	Mean Deviation	3,673,104
	Median	(4,511,000)
	Standard Deviation	4,047,990
	Sample Variance	16.4T
	Range	11.9M
	R-Value	0.84
	Mean Square Error	5.2T
	R-Squared	0.71
	Significance	0.000089
	Slope	760,377
	Total Sum of Squares	229.4T

Crinetics Gross Profit History

	2024	4.2 M
	2023	4 M
	2022	4.7 M
	2021	1.1 M
	2020	71 K
	2019	1.2 M
	2018	2.4 M

Other Fundumenentals of Crinetics Pharmaceuticals

Gross Profit Margin

Crinetics Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue
Total Assets		0.5	0.95	-0.17	-0.98	0.78	-0.81	0.95	-0.81	0.83	0.86	-0.81	1.0	0.94	0.98	0.72	1.0	1.0	0.9	-0.79	0.98	0.83
Total Stockholder Equity	0.5		0.24	0.48	-0.47	0.06	-0.83	0.73	-0.83	0.14	0.8	-0.83	0.47	0.74	0.48	0.02	0.45	0.46	0.7	-0.07	0.48	0.44
Net Tangible Assets	0.95	0.24		-0.39	-0.93	0.84	-0.63	0.82	-0.63	0.92	0.67	-0.63	0.97	0.81	0.93	0.83	0.97	0.97	0.75	-0.87	0.93	0.75
Net Debt	-0.17	0.48	-0.39		0.09	-0.22	-0.23	0.07	-0.23	-0.41	0.27	-0.23	-0.2	0.07	-0.14	-0.43	-0.23	-0.21	0.24	0.44	-0.14	0.26
Retained Earnings	-0.98	-0.47	-0.93	0.09		-0.81	0.78	-0.93	0.78	-0.77	-0.88	0.78	-0.98	-0.92	-0.99	-0.67	-0.97	-0.98	-0.92	0.8	-0.99	-0.9
Accounts Payable	0.78	0.06	0.84	-0.22	-0.81		-0.39	0.65	-0.39	0.86	0.51	-0.39	0.79	0.65	0.8	0.9	0.8	0.79	0.59	-0.92	0.8	0.72
Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39		-0.92	1.0	-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Net Receivables	0.95	0.73	0.82	0.07	-0.93	0.65	-0.92		-0.92	0.71	0.95	-0.92	0.94	1.0	0.93	0.59	0.93	0.94	0.94	-0.66	0.93	0.82
Long Term Debt Total	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92		-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Capital Surpluse	0.83	0.14	0.92	-0.41	-0.77	0.86	-0.49	0.71	-0.49		0.48	-0.49	0.85	0.7	0.77	0.97	0.87	0.85	0.54	-0.88	0.77	0.57
Total Liab	0.86	0.8	0.67	0.27	-0.88	0.51	-0.93	0.95	-0.93	0.48		-0.93	0.84	0.96	0.87	0.35	0.81	0.83	0.97	-0.49	0.87	0.85
Short Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92	1.0	-0.49	-0.93		-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Total Current Assets	1.0	0.47	0.97	-0.2	-0.98	0.79	-0.79	0.94	-0.79	0.85	0.84	-0.79		0.93	0.98	0.74	1.0	1.0	0.88	-0.81	0.98	0.83
Short Term Debt	0.94	0.74	0.81	0.07	-0.92	0.65	-0.91	1.0	-0.91	0.7	0.96	-0.91	0.93		0.92	0.58	0.92	0.93	0.93	-0.65	0.92	0.81
Common Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92		0.68	0.97	0.98	0.91	-0.82	1.0	0.87
Property Plant Equipment	0.72	0.02	0.83	-0.43	-0.67	0.9	-0.32	0.59	-0.32	0.97	0.35	-0.32	0.74	0.58	0.68		0.76	0.74	0.4	-0.9	0.68	0.47
Net Invested Capital	1.0	0.45	0.97	-0.23	-0.97	0.8	-0.77	0.93	-0.77	0.87	0.81	-0.77	1.0	0.92	0.97	0.76		1.0	0.86	-0.82	0.97	0.81
Net Working Capital	1.0	0.46	0.97	-0.21	-0.98	0.79	-0.78	0.94	-0.78	0.85	0.83	-0.78	1.0	0.93	0.98	0.74	1.0		0.88	-0.81	0.98	0.82
Short Term Investments	0.9	0.7	0.75	0.24	-0.92	0.59	-0.89	0.94	-0.89	0.54	0.97	-0.89	0.88	0.93	0.91	0.4	0.86	0.88		-0.53	0.91	0.93
Deferred Long Term Liab	-0.79	-0.07	-0.87	0.44	0.8	-0.92	0.45	-0.66	0.45	-0.88	-0.49	0.45	-0.81	-0.65	-0.82	-0.9	-0.82	-0.81	-0.53		-0.82	-0.58
Capital Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92	1.0	0.68	0.97	0.98	0.91	-0.82		0.87
Current Deferred Revenue	0.83	0.44	0.75	0.26	-0.9	0.72	-0.73	0.82	-0.73	0.57	0.85	-0.73	0.83	0.81	0.87	0.47	0.81	0.82	0.93	-0.58	0.87

Click cells to compare fundamentals

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	4 M	4.2 M
Gross Profit Margin	0.81	0.85

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC